Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RNXT Stock Forecast 2026-2027
$0.84
Current Price
$38.05M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RNXT Price Targets
+1,558.8%
To High Target of $14.00
+558.8%
To Median Target of $5.56
+255.5%
To Low Target of $3.00
RNXT Price Momentum
-5.6%
1 Week Change
+2.4%
1 Month Change
-35.4%
1 Year Change
0.0%
Year-to-Date Change
-41.8%
From 52W High of $1.45
+20.4%
From 52W Low of $0.70
📊 TOP ANALYST CALLS
Did RNXT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if RenovoRx is one of their latest high-conviction picks.
Latest RNXT Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, RNXT has a bullish consensus with a median price target of $5.56 (ranging from $3.00 to $14.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.84, the median forecast implies a 558.8% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 1,558.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RNXT Analyst Ratings
4
Buy
0
Hold
0
Sell
RNXT Price Target Range
Low
$3.00
Average
$5.56
High
$14.00
Current: $0.84
Latest RNXT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RNXT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | Edward Woo | Buy | Maintains | $14.00 |
| Apr 9, 2026 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Apr 8, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 17, 2026 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Nov 21, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Aug 25, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Jun 5, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| May 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 28, 2025 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 27, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Dec 10, 2024 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Sep 12, 2024 | Ascendiant Capital | Buy | Maintains | $N/A | |
| Jun 17, 2024 | Ascendiant Capital | Buy | Initiates | $N/A | |
| Feb 2, 2024 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Nov 15, 2023 | Maxim Group | Hold | Downgrade | $N/A | |
| Aug 18, 2023 | Roth MKM | Buy | Maintains | $N/A | |
| Nov 1, 2021 | Roth Capital | Buy | Initiates | $N/A | |
| Oct 6, 2021 | Maxim Group | Buy | Initiates | $N/A |
RenovoRx Inc. (RNXT) Competitors
The following stocks are similar to RenovoRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RenovoRx Inc. (RNXT) Financial Data
RenovoRx Inc. has a market capitalization of $38.05M with a P/E ratio of -2.6x. The company generates $1.49M in trailing twelve-month revenue with a 70.9% profit margin.
Revenue growth is +185.8% quarter-over-quarter, while maintaining an operating margin of -616.2% and return on equity of -100.5%.
Valuation Metrics
Market Cap
$38.05M
Enterprise Value
$25.88M
P/E Ratio
-2.6x
PEG Ratio
-0.2x
Price/Sales
25.6x
Growth & Margins
Revenue Growth (YoY)
+185.8%
Gross Margin
+85.1%
Operating Margin
-616.2%
Net Margin
+70.9%
EPS Growth
+185.8%
Financial Health
Cash/Price Ratio
+32.5%
Current Ratio
7.1x
Debt/Equity
1.7x
ROE
-100.5%
ROA
-51.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
RenovoRx Inc. (RNXT) Business Model
About RenovoRx Inc.
What They Do
Develops innovative cancer therapies using targeted delivery.
Business Model
RenovoRx Inc. generates revenue by developing and commercializing its proprietary cancer treatment platform, particularly the Trans-Arterial Micro-Perfusion (TAMP) system, which delivers targeted chemotherapy to tumors. The company aims to secure funding through clinical trials and regulatory approvals, ultimately leading to product sales and licensing agreements within the oncology market.
Additional Information
The company focuses on difficult-to-treat cancers, especially pancreatic cancer, and is committed to improving survival rates and patient quality of life. By advancing precision medicine, RenovoRx is positioned as a key player in the biotechnology sector, with ongoing efforts to validate its innovative therapies through regulatory pathways and clinical trials.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Mr. Shaun R. Bagai
Country
United States
IPO Year
2021
Website
renovorx.comRenovoRx Inc. (RNXT) Latest News & Analysis
Latest News
Quick Summary
RenovoRx, Inc. announced news from Mountain View, California, on June 11, 2026. Further details were not provided in the excerpt.
Why It Matters
RenovoRx, Inc.'s news may indicate developments in their business strategy, financial performance, or product pipeline, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
RenovoRx, Inc. (Nasdaq: RNXT) will have CEO Shaun Bagai present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026.
Why It Matters
RenovoRx's CEO presentation at a key investment conference highlights the company's visibility and potential for growth in the oncology sector, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
18 days ago
Quick Summary
RenovoRx received its third FDA Orphan Drug Designation, advancing its oncology pipeline and securing seven years of market exclusivity for its therapeutic developments.
Why It Matters
RenovoRx's third FDA Orphan Drug Designation enhances its oncology pipeline, potentially leading to increased market share and revenue due to seven years of exclusive rights for the drug.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A Phase III TIGeR-PaC trial sub-study supports TAMP for targeted delivery of Gemcitabine, suggesting increased local drug potency and reduced systemic side effects.
Why It Matters
The promising results of the TIGeR-PaC trial could enhance the market potential for gemcitabine, impacting pharmaceutical stock valuations and investor sentiment in oncology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
27 days ago
Quick Summary
RenovoRx, Inc. (Nasdaq: RNXT) will present at the Alliance Global Partners Annual Healthcare Company Showcase on May 20, 2026. CEO Shaun Bagai and CFO Mark Voll will participate.
Why It Matters
RenovoRx's participation in the AGP Healthcare Showcase highlights its leadership engagement, potentially boosting investor confidence and interest in its oncology therapies and growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
1 month ago
Quick Summary
In Q1 2026, revenue reached $563,000, over 50% of 2025's total. Active cancer center customers increased to 16. The Phase III trial is fully enrolled. Cash reserves of $12.4 million support operations through mid-2027.
Why It Matters
Revenue growth exceeding 50% year-over-year indicates strong market demand. Expansion in customers and cash reserves suggest operational stability, boosting confidence in future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RNXT Stock
What is RenovoRx Inc.'s (RNXT) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, RenovoRx Inc. (RNXT) has a median price target of $5.56. The highest price target is $14.00 and the lowest is $3.00.
Is RNXT stock a good investment in 2026?
According to current analyst ratings, RNXT has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RNXT stock?
Wall Street analysts predict RNXT stock could reach $5.56 in the next 12 months. This represents a 558.8% increase from the current price of $0.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is RenovoRx Inc.'s business model?
RenovoRx Inc. generates revenue by developing and commercializing its proprietary cancer treatment platform, particularly the Trans-Arterial Micro-Perfusion (TAMP) system, which delivers targeted chemotherapy to tumors. The company aims to secure funding through clinical trials and regulatory approvals, ultimately leading to product sales and licensing agreements within the oncology market.
What is the highest forecasted price for RNXT RenovoRx Inc.?
The highest price target for RNXT is $14.00 from Edward Woo at Ascendiant Capital, which represents a 1,558.8% increase from the current price of $0.84.
What is the lowest forecasted price for RNXT RenovoRx Inc.?
The lowest price target for RNXT is $3.00 from at , which represents a 255.5% increase from the current price of $0.84.
What is the overall RNXT consensus from analysts for RenovoRx Inc.?
The overall analyst consensus for RNXT is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.56.
How accurate are RNXT stock price projections?
Stock price projections, including those for RenovoRx Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 3:49 AM UTC